Medicine
Symbravo 20 mg/10 mg tablet
Symbravo 20 mg/10 mg tablet is a prescription medicine containing Meloxicam and Rizatriptan for oral use, marketed by Axsome Therapeutics, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store SYMBRAVO in the original bottle at 20°C to 25°C (68°F to 77°F)…
Key facts
- Active ingredient (INN)
- Meloxicam and Rizatriptan
- Brand
- Symbravo
- Strength
- 20 mg/10 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 9 tablets
- Marketing authorisation holder
- Axsome Therapeutics
- Manufacturer
- Axsome Therapeutics
- Origin register
- US FDA, United States
- Storage
- Store SYMBRAVO in the original bottle at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 19 May 2025
- Identifiers
- RxCUI 2711789, 2711795DailyMed set ID dcf1ecd1-08a0-8e47-e053-2a95a90abdc7NDC 81968-020Application NDA215431
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 9 tablet in 1 bottle | 81968-020-09 | Axsome Therapeutics | 19 May 2025 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 30 January 2025 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Meloxicam and Rizatriptan is a fixed-dose combination of a nonsteroidal anti-inflammatory drug and a serotonin-1b and serotonin-1d receptor agonist indicated for the acute treatment of migraine with or without aura in adults. MedsAcross supplies Meloxicam and Rizatriptan for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Meloxicam and RizatriptanFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- SYMBRAVO prescribing information (Axsome Therapeutics) · U.S. National Library of Medicine, DailyMed
Need Symbravo 20 mg/10 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.